• Z-VDVAD-FMK: Apoptosis Pathway Mapping

  2026-09-11

  Z-VDVAD-FMK helps researchers distinguish caspase-2-linked mitochondrial apoptosis from downstream caspase-3/7 activity and caspase-independent death. This workflow also shows how to use it as a mechanistic control when studying HOXC8-associated pyroptosis in lung cancer models.

• Bedaquiline: An Energy-Centered Assay Framework

  2026-09-10

  Bedaquiline is a diarylquinoline antibiotic whose energy-targeting mechanism supports a rigorous framework for tuberculosis and cancer-metabolism research. This article distinguishes direct bacterial ATP-synthase inhibition from host-directed GSK3 biology and translates both into practical assay decisions.

• Haloprogin: Evidence from a Foundational Antifungal Study

  2026-09-10

  The 1970 study by Harrison and colleagues established Haloprogin as a topical antifungal with dermatophyte activity comparable to tolnaftate, while also demonstrating activity against Candida species and selected Gram-positive bacteria. Its combination of serial-dilution testing, fungicidal endpoints, and steroid-maintained guinea pig infection models provides a useful framework for interpreting spectrum, formulation, and translational limitations.

• Morin: A Mechanism-First Neuroinflammation Probe

  2026-09-09

  Morin is a natural flavonoid antioxidant with applications spanning oxidative-stress biology, mitochondrial metabolism, and fluorescent aluminum detection. This article presents a phenotype-first framework for using Morin in neurological and metabolic disease assays without confusing preclinical mechanism with clinical treatment.

• LG 101506 (RXR modulator) in Cell Assays

  2026-09-09

  A scenario-based guide to using LG 101506 (RXR modulator), SKU B7414, in cell viability, proliferation, and cytotoxicity workflows. It covers formulation controls, protocol design, interpretation, and evidence boundaries for RXR signaling pathway research.

• LY2603618: A Biomarker-Led Chk1 Assay Strategy

  2026-09-08

  LY2603618 is a selective Chk1 inhibitor for investigating replication stress, checkpoint dependence, and chemotherapy sensitization. This article develops a biomarker-led assay framework based on PPP2R2A biology, helping researchers distinguish genuine Chk1 dependency from nonspecific DNA damage.

• miR-3180 Rewires Lipid Metabolism in HCC

  2026-09-08

  Hong et al. show that miR-3180 suppresses hepatocellular carcinoma by simultaneously limiting SCD1-dependent fatty acid synthesis and CD36-mediated lipid uptake. The study combines patient-tissue analysis, mechanistic reporter assays, functional cancer-cell experiments, lipid measurements, and xenograft validation to connect one microRNA with two complementary metabolic inputs.

• Dacarbazine: Mechanism, Evidence, and Workflow

  2026-09-07

  Dacarbazine is an antineoplastic chemotherapy drug that produces DNA damage after metabolic activation. Its research value depends on separating growth inhibition from cell killing in controlled viability assays.

• Gepotidacin for Uncomplicated Urogenital Gonorrhea

  2026-09-07

  This phase 2 randomized study evaluated whether a single oral dose of gepotidacin could eradicate uncomplicated urogenital Neisseria gonorrhoeae infection. Both tested doses produced at least 95% microbiological eradication in the evaluable population, while failures shared a higher observed MIC and a common gene mutation, highlighting both the promise and resistance-monitoring needs of this novel mechanism.

• Ibrexafungerp Activity Against Resistant Candida auris

  2026-09-05

  Wiederhold and colleagues evaluated ibrexafungerp against fluconazole-resistant Candida auris using broth microdilution and a delayed-treatment neutropenic mouse model. The study found consistent in vitro activity and meaningful in vivo efficacy, supporting glucan synthase inhibition as a strategy for difficult-to-treat invasive candidiasis while highlighting the limits of extrapolating animal results to clinical care.

• CUDC-907: Practical PI3K/HDAC Workflow

  2026-09-04

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of pathway signaling, acetylation, cell-cycle distribution, and apoptosis in cancer cell models. This guide translates the supplied product dossier into an executable workflow and defines handling, QC, and interpretation limits; the compound is not intended for diagnostic, therapeutic, or clinical use.

• Apicidin Disrupts Oocyte Maturation and Histone Acetylation

  2026-09-04

  The 2026 reference study identifies a reproductive-toxicity mechanism for Apicidin by linking impaired oocyte meiotic maturation with spindle, chromosome, actin, DNA-damage, and histone-acetylation abnormalities. Its findings expand evaluation of this histone deacetylase inhibitor beyond somatic-cell toxicity and emphasize the need to distinguish epigenetic activity from reproductive safety.

• MiR-3180 Rewires Lipid Metabolism in HCC

  2026-09-03

  Hong et al. identify miR-3180 as a coordinated regulator of fatty-acid synthesis and uptake in hepatocellular carcinoma by targeting SCD1 and CD36. The study links reduced miR-3180 expression with aggressive tumor behavior and poorer prognosis, while integrating tissue analyses, molecular assays, lipid phenotyping, cell models, and xenograft validation.

• Toremifene Workflows for Prostate Cancer Research

  2026-09-03

  Toremifene is a practical selective estrogen-receptor modulator for linking hormone-response measurements with cell growth, migration, invasion, and calcium-signaling assays. This workflow guide shows how to build concentration-response studies, interpret the TSPAN18-STIM1 metastasis mechanism, and troubleshoot experiments without implying that Toremifene directly targets that pathway.

• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-09-02

  The Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, supports targeted HMGB1 detection in human, mouse, and rat research samples by Western blot, immunohistochemistry, and flow cytometry. It is an unconjugated research reagent and should not be used for diagnosis, therapy, or other medical purposes.

8087 records 1/540 page Next 12345 下5页 Last page